



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

**\*BIBDATASHEET\***

CONFIRMATION NO. 2403

Bib Data Sheet

SERIAL NUMBER 10/076,575	FILING DATE 02/08/2002  RULE	CLASS 514	GROUP ART UNIT 1624	ATTORNEY DOCKET NO. 5698.220-US	
<b>APPLICANTS</b>  Lone Jeppesen, Virum, DENMARK;  Paul Stanley Bury, Kobenhavn, DENMARK; Per Sauerberg, Farum, DENMARK;  <b>** CONTINUING DATA *****</b> This application is a DIV of 09/419,761 10/19/1999 PAT 6,468,996 and claims benefit of 60/105,912 10/28/1998  <b>** FOREIGN APPLICATIONS *****</b> DENMARK PA 1998 01352 10/21/1998  <b>IF REQUIRED, FOREIGN FILING LICENSE GRANTED</b> <b>** 03/07/2002</b>					
Foreign Priority claimed <input checked="" type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions met <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance Verified and Acknowledged <u>Brenda Coleman</u> <u>BC</u> Examiner's Signature Initials		STATE OR  COUNTRY DENMARK	SHEETS  DRAWING 0	TOTAL  CLAIMS 10	INDEPENDENT  CLAIMS 1
<b>ADDRESS</b> Reza Green, Esq. Novo Nordisk of North America, Inc. 100 College Rd. W. Princeton, NJ 08540-6604					
<b>TITLE</b> Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators					
FILING FEE  RECEIVED 740	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		